title: Evaluation of a mobile phone-based, advanced symptom management system (ASyMS) in the management of chemotherapy-related toxicity.
abstract: OBJECTIVE
  To evaluate the impact of a mobile phone-based, remote monitoring, advanced symptom management system (ASyMS) on the incidence, severity and distress of six chemotherapy-related symptoms (nausea, vomiting, fatigue, mucositis, hand-foot syndrome and diarrhoea) in patients with lung, breast or colorectal cancer.
  
  
  METHODS
  A two group (intervention and control) by five time points (baseline, pre-cycle 2, pre-cycle 3, pre-cycle 4 and pre-cycle 5) randomised controlled trial.
  
  
  METHODS
  Seven clinical sites in the UK; five specialist cancer centres and two local district hospitals.
  
  
  METHODS
  One hundred and twelve people with breast, lung or colorectal cancer receiving outpatient chemotherapy.
  
  
  METHODS
  A mobile phone-based, remote monitoring, advanced symptom management system (ASyMS).
  
  
  METHODS
  Chemotherapy-related morbidity of six common chemotherapy-related symptoms (nausea, vomiting, fatigue, mucositis, hand-foot syndrome and diarrhoea).
  
  
  RESULTS
  There were significantly higher reports of fatigue in the control group compared to the intervention group (odds ratio = 2.29, 95%CI = 1.04 to 5.05, P = 0.040) and reports of hand-foot syndrome were on average lower in the control group (odds ratio control/intervention = 0.39, 95%CI = 0.17 to 0.92, P = 0.031).
  
  
  CONCLUSIONS
  The study demonstrates that ASyMS can support the management of symptoms in patients with lung, breast and colorectal cancer receiving chemotherapy.
authors.affiliation: Cancer Care Research Centre, Department of Nursing and Midwifery, University of Stirling, Stirling FK9 4LA, UK, nora.kearney@stir.ac.uk
authors.forename: N
authors.initials: N
authors.lastname: Kearney
authors.forename: L
authors.initials: L
authors.lastname: McCann
authors.forename: J
authors.initials: J
authors.lastname: Norrie
authors.forename: L
authors.initials: L
authors.lastname: Taylor
authors.forename: P
authors.initials: P
authors.lastname: Gray
authors.forename: M
authors.initials: M
authors.lastname: McGee-Lennon
authors.forename: M
authors.initials: M
authors.lastname: Sage
authors.forename: M
authors.initials: M
authors.lastname: Miller
authors.forename: R
authors.initials: R
authors.lastname: Maguire
mesh_terms: D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000188:drug therapy; D040421:Cell Phone; D015179:Colorectal Neoplasms / Q000188:drug therapy; D016903:Drug Monitoring / Q000379:methods*; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D010865:Pilot Projects; D012720:Severity of Illness Index; D017216:Telemedicine / Q000379:methods; D006113:United Kingdom / Q000453:epidemiology
chemical_list: D000970:Antineoplastic Agents